Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EvAluation of the efficacy of MaaT013 as salvage theRapy in acute GVHD patiEntS with gastrointestinal involvement, refractory to ruxolitinib
2024-513023-17-00Phase 3Completed
- Sponsor
- MaaT Pharma
- Start
- Jan 2022
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 6
01
Overview
Phase 3, open-label, single-arm trial of MaaT013 in graft-versus-host disease (GVHD), sponsored by MaaT Pharma. Primary endpoint: Overall response rate of gastrointestinal acute graft-versus-host disease at day 28. Started Jan 2022; status: completed.
02
Drugs
MaaT013
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on 2024-513023-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513023-17-00.